Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.

@article{Sundkvist1992PeripheralAA,
  title={Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.},
  author={Gunilla M. G. Sundkvist and Fred M. Armstrong and J. E. Bradbury and Connie Chaplin and S. H. Ellis and David R. Owens and Ingmar Ros{\'e}n and Peter S{\"o}nksen},
  journal={Journal of diabetes and its complications},
  year={1992},
  volume={6 2},
  pages={
          123-30
        }
}
The potential of the aldose reductase inhibitor ponalrestat (600 mg daily) to ameliorate diabetic neuropathy was evaluated in 259 diabetes mellitus patients with peripheral neuropathy (defined by abnormal vibration perception threshold and abnormal peroneal motor conduction velocity) in a double-blind placebo-controlled clinical trial running for 18 months. Overall, no beneficial effect of ponalrestat on vibration perception thresholds, nerve conduction velocities, and nerve action potential… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Status of current clinical trials in diabetic polyneuropathy.

  • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • 2001